Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23352170 | 0.90 | PLA2G2A (0.64) | PLA2G2AMAPTKMT2AMEN1PKM | |
| SCHEMBL39013 | 0.88 | MAPT (0.60) | PLA2G2AALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL27994057 | 0.87 | PLA2G2A (0.59) | PLA2G2AMAPTKMT2AMEN1PKM | |
| SCHEMBL38560 | 0.86 | MAPT (0.54) | PLA2G2AALDH1A1MAPTMRGPRX4NPC1 | |
| SCHEMBL5225023 | 0.86 | MAPT (0.48) | PLA2G2AALDH1A1MAPTNPC1RECQL | |
| SCHEMBL5224719 | 0.86 | PLA2G2A (0.64) | PLA2G2AALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL12733612 | 0.85 | PLA2G2A (0.58) | PLA2G2AALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL90428 | 0.85 | PLA2G2A (0.58) | PLA2G2AKMT2AMEN1PKMMRGPRX4 | |
| SCHEMBL29788135 | 0.85 | PLA2G2A (0.58) | PLA2G2AKMT2AMEN1PKMMRGPRX4 | |
| SCHEMBL2564264 | 0.84 | PLA2G2A (0.57) | PLA2G2AALDH1A1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PLA2G2A 879/4885ALDH1A1 3466/4885MAPT 659/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PLA2G2A 879/4885ALDH1A1 3466/4885MAPT 659/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PLA2G2A 879/4885ALDH1A1 3466/4885MAPT 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.